Healthcare >> CEO Interviews >> November 18, 2014
William Hunter, M.D., has been a member of Cardiome Pharma Corp.'s board of directors since 2007, and became the company's President and CEO in July 2012. Prior to Cardiome, Dr. Hunter co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of Chief Executive Officer in 1997. He led Angiotech through venture financing; the company’s IPO, and listing on the Toronto Stock Exchange and Nasdaq; over $1 billion in subsequent equity and debt financings; a debt restructuring; and eight separate corporate acquisitions. Dr. Hunter has over 200 patents and patent applications to his name, and products in which he was an inventor or co-inventor include the TAXUS Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter. Dr. Hunter also served as a practicing physician in British Columbia for five years. Profile
Dr. Hunter: The company was founded around a treatment for atrial fibrillation — AF. It has a drug
